RetinalaminРетиналамин
A retinal tissue polypeptide extract studied in people with retinal disease, including age-related macular degeneration and pigmentary retinal dystrophy. Studies distinguish injected Retinalamin from oral Normophthal.
What the studies found
Randomized study in people · 2026
Retinalamin versus placebo over two years in 21 patients with age-related macular degeneration
- Dry AMD mean retinal light sensitivity
- +3.27 ± 1.03 dB with Retinalamin−4.14 ± 2.11 dB with placeboDay 720Between-arm difference in change +7.41 dB (p < 0.001)
- Wet AMD mean retinal light sensitivity
- The within-arm increase with Retinalamin was inconclusive (p = 0.302)−3.57 ± 0.94 dB with placeboDay 720Reported between-arm difference in change +5.57 dB (p < 0.001)
- Dry AMD eyes without relative blind spots on testing
- 27.3% to 100% with Retinalamin (p = 0.002)All placebo eyes had relative blind spots by day 180
At 720 days, mean light sensitivity in dry AMD eyes rose by 3.27 dB with Retinalamin and fell by 4.14 dB with placebo, a reported difference in change of 7.41 dB (p < 0.001). In treated wet AMD eyes, the within-group increase was statistically inconclusive (p = 0.302).
More reported outcomes
- Companion electroretinography report
- The authors describe differences favoring Retinalamin across most electrical response measures.Exact estimates for individual electrical endpoints require the full tables.
Study notes · methods, sources and limitations
Participants or model 21 people, each with dry AMD in one eye and wet AMD in the other. Retinalamin: 11 people (22 eyes). Placebo: 10 people (20 eyes).
Design Randomized comparison with threshold microperimetry at 76 retinal locations using the Nidek MP-3. Follow-up visits ran from day 90 to day 720. Dry and wet measurements came from fellow eyes in the same participants.
Important limitations
- The two supplement papers match on sample size, eye diagnoses, intervention and 720-day follow-up, and the microperimetry paper cites the electroretinography paper. They are treated as one cohort. The relationship to the larger RetinGero trial remains unconfirmed. The abstracts leave masking, withdrawals, other eye treatments and adverse-event counts unclear. The study results describe how the retina responded to testing. Effects on visual acuity and disease progression remain unclear.
Russian Ophthalmological Journal. 2026;19(4 Suppl):33–40. · Original journal report
Comparison in people · 2024
Retinalamin in diabetic retinopathy: three-month imaging and electrical responses
- Ganglion-cell complex (GCL++)
- 105.45 to 109.14 µm at month 3103.46 to 101.50 µm in controlsp = 0.047 for treated group versus baseline
- Full-field ERG magnitude
- 0.77 to 0.87 µV at month 30.91 to 0.88 µV in controlsp = 0.0489 for treated group versus baseline
- Ganglion-cell and inner plexiform layers (GCL+)
- 63.69 µm at baseline, 61.55 µm at month 1, 65.79 µm at month 365.04, 64.50 and 63.43 µm in controls
At three months, mean ganglion-cell complex thickness went from 105.45 to 109.14 µm with Retinalamin and from 103.46 to 101.50 µm in controls. The paper reports p = 0.047 for change within the treated group.
Study notes · methods, sources and limitations
Participants or model 56 people with type 1 or type 2 diabetes and retinopathy without active macular edema. Retinalamin and comparison arms each included 28 people (56 eyes).
Design Patients received ten daily intramuscular injections or were followed without Retinalamin. The team used optical coherence tomography (OCT) and pattern and full-field electroretinography (ERG) at baseline, month 1 and month 3.
Important limitations
- The authors explicitly reuse the clinical groups from their earlier functional paper. These are two reports on one 56-person cohort. The groups start with different retinal electrical readings. The reported p values compare treated patients with their own baseline. The paper leaves group assignment, masking and the handling of measurements from both eyes unclear. These measures track retinal structure and electrical function. The data leave vision preservation and long-term disease progression unanswered.
Vestnik Oftalmologii. 2024;140(5):97–104. · Original journal report
Observational study · 2015
Retinalamin in retinal dystrophy: a 46-patient long-term comparison
- Visual acuity improved after the first course
- 18/31 (58.1%) with Retinalamin and 4/15 (26.7%) with conventional medications, calculated from the visual acuity categories in Table 1.
- Retinal pigmentary degeneration at long-term follow-up
- After 23–25 years of Retinalamin, 5/9 had residual vision (0.02–0.04), 1/9 had object vision (0.1 or higher) and 3/9 had complete blindness. All 11 conventional-care patients in this diagnostic subgroup had complete blindness.
- Pigmentary degeneration after shorter exposure
- Of 15 who received Retinalamin for the first 5–7 years, 5 retained residual vision and 10 had complete blindness at long-term assessment.
Visual acuity improved after the first course in 18/31 Retinalamin recipients and 4/15 comparison patients. After 23–25 years, 6/9 patients with pigmentary retinal dystrophy in the longer-treatment group had residual or object vision versus 0/11 comparison patients.
Study notes · methods, sources and limitations
Participants or model 46 patients (92 eyes): 20 received Retinalamin for 5–7 years, 11 for 23–25 years, and 15 received conventional care.
Design Retinalamin 5 mg by parabulbar injection daily for 10 days (50 mg per course), repeated one to two times per year. The paper compares 20 people with 5–7 years of courses, 11 with 23–25 years of courses and 15 given conventional medications.
Important limitations
- Treatment groups were defined by access to repeated courses. Selection, baseline differences and retention can influence the long-term comparison. The paper reports patients and eyes separately. The reported outcomes do not establish a separate independent effect for each eye. This study examines pigmentary degeneration and retinal abiotrophy, distinct diagnoses from the early macular degeneration dissertation.
- The long-term comparison is observational. Duration groups reflect access to repeated courses, with potential differences in baseline severity and retention.
Ophthalmology in Russia. 2015;12(2):43–47. The DOI string carries a different page range. · Original journal report
About Retinalamin
Names in this research collection
Retinal polypeptide complex
Organ-derived peptide research: clinical findings and lineage ↗
Research background
A retinal tissue-derived peptide preparation studied in ophthalmology. It is distinct from the short-peptide catalogue entry Normophthal.
More study findings
Comparison in people · 2016
One versus two Retinalamin courses in dry age-related macular degeneration
- Multifocal electroretinography in early or intermediate AMD
- Favorable change reported in 80% of casesPeak two months after the first course
- Multifocal electroretinography in atrophic AMD
- Favorable change in more than 70% of cases after the repeat coursePeak at month 5
In 90 patients, the authors reported improved retinal electrical responses in 80% of early or intermediate cases after treatment. More than 70% of atrophic cases improved after the repeat course.
Study notes · methods, sources and limitations
Participants or model 90 adults aged 47–75 with dry AMD, contributing 180 eyes. One course: 30 people. Repeat course: 60 people.
Design The Helmholtz institute group compared one versus two courses over six months using multifocal electroretinography and other eye assessments.
Important limitations
- Both groups received active drug. Percentages refer to disease-stage groups described in the paper. Eyes from the same patient are correlated. The retinal electrical response does not establish slower progression or less vision loss.
Russian Ophthalmological Journal. 2016;(1):39–46. · Publication record
Trial protocol and enrollment update · 2025
RetinGero dry AMD trial: protocol and preliminary enrollment
RetinGero plans a 240-person placebo-controlled comparison. The protocol article reports 187 enrolled and baseline data for 170 as of January 3, 2025. Comparative efficacy results are pending in the checked publication.
Study notes · methods, sources and limitations
Participants or model Adults aged 60–80 with early or intermediate dry AMD in the study eye and a history of wet AMD in the fellow eye. 240 planned, 120 per group.
Design Multicenter double-blind randomized comparison. The Mandryka military hospital ophthalmology center coordinates the trial with Pirogov University. Assessments include visual acuity, contrast sensitivity, OCT drusen measures and conversion to advanced AMD.
- Planned randomization
- 240 participants, 120 per arm
- Documented enrollment and baseline data
- 187 enrolled. Baseline data available for 170 (84 and 86 by masked group).January 3, 2025
- Completed the full cycle
- 4 participantsSeptember 1, 2025
Important limitations
- Screening, enrollment, available baseline data and completion represent different denominators. The protocol article gives no between-group efficacy result.
- The published figures describe recruitment and data availability.
Russian Journal of Clinical Ophthalmology. 2025;25(4):250–256. · Published trial protocol and recruitment update
Comparison in people · 2022
Retinalamin schedules and visual-field testing in advanced glaucoma
- Retinal photosensitivity
- No statistically significant change
- Mean deviation across testing programs
- −0.36 dB95% CI −4.27 to 3.54
Retinal photosensitivity did not change significantly in this 17-patient schedule comparison. Both groups received Retinalamin.
Study notes · methods, sources and limitations
Participants or model 17 adults with advanced primary open-angle glaucoma, 34 eyes. Nine received courses every three months and eight every six months.
Design Two active schedules compared with automated visual-field testing on different devices and programs.
Important limitations
- No untreated arm. The 2024 OCT report has the same center, group sizes and schedules. It likely describes the same subgroup.
Russian Open Medical Journal. 2022;11:e0109. · Publication record
Comparison in people · 2024
Retinalamin schedules and OCT measurement agreement in advanced glaucoma
- Retinal nerve fiber layer thickness agreement
- 0.69 manual and 0.73 automatic95% CI 0.51–0.81 and 0.57–0.84, respectively
- Macular volume agreement
- 0.21 in both modes
Baseline agreement between OCT devices for retinal nerve fiber layer thickness was 0.69 in manual mode and 0.73 in automatic mode. Agreement for macular volume was 0.21 in both modes.
Study notes · methods, sources and limitations
Participants or model 17 adults, 34 eyes. Nine patients on the three-month schedule and eight on the six-month schedule.
Design Investigators used two OCT systems, tested manual and automated segmentation, and calculated Lin’s concordance correlation coefficients.
Important limitations
- Both groups received Retinalamin. Device agreement does not establish clinical benefit. The same center and schedules appear in the 2022 visual-field report.
Russian Open Medical Journal. 2024;13:e0307. · Publication record
Laboratory analysis · 2017
Measured amino acids in organ peptide preparations
Study of multiple preparations
- Retinalamin · measured amino-acid total
- 563.74 µg/mg lyophilizateTable 2 comparator; taurine 4.1 µg/mg, ornithine not displayed.
This is analytical chemistry, with hydrolysis-released amino acids.
Study notes · methods, sources and limitations
Participants or model Laboratory composition comparison of Cortexin, Cerebrolysin, Retinalamin and Pineamin; three Pineamin manufacturing batches
Design Laboratory composition comparison of Cortexin, Cerebrolysin, Retinalamin and Pineamin; three Pineamin manufacturing batches
Important limitations
- The comparison does not identify intact peptide sequences or predict effects.
- Amino-acid totals are not the molecular-mass distribution or an inventory of intact peptides. The mass denominator and formulation excipients matter when comparing liquid and lyophilized organ preparations. Some values in the published table conflict.
- Chemical characterization helps distinguish the preparations. It cannot establish that amino-acid contents explain stress resistance, and it does not identify which peptides were present.
Bulletin of the Russian Military Medical Academy. 19(1):129–136 · Original journal article
Performance research in context
- Compound class
- Tissue-derived polypeptide complex
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- St. Petersburg Institute of Bioregulation and Gerontology
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Randomized glaucoma studies and a prospective advanced-glaucoma cohort
Study methods
Clinical findings are mixed; within-group and between-group results are distinguished
Independent replication
Independent replication not established by this collection
Source access
Indexed original abstracts, publisher sources and linked PDFs
Safety evidence
Incomplete assessment; findings do not establish safety for personal use
Open a topic for the evidence assessment.
Patents and claimed inventions
These 2 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Comparison in people · 2024
Retinalamin in diabetic retinopathy: three-month imaging and electrical responses
At three months, mean ganglion-cell complex thickness went from 105.45 to 109.14 µm with Retinalamin and from 103.46 to 101.50 µm in controls. The paper reports p = 0.047 for change within the treated group.
Ganglion-cell complex (GCL++) · 105.45 to 109.14 µm at month 3 · 103.46 to 101.50 µm in controls · p = 0.047 for treated group versus baseline
Study notes and original source
Retinalamin in diabetic retinopathy: three-month imaging and electrical responses
Intramuscular Retinalamin (Geropharm) · Original journal report
A. I. Malakhova, V. V. Strakhov, Y. A. Malakhova · Vestnik Oftalmologii. 2024;140(5):97–104.
At three months, mean ganglion-cell complex thickness went from 105.45 to 109.14 µm with Retinalamin and from 103.46 to 101.50 µm in controls. The paper reports p = 0.047 for change within the treated group.
Results and tables
Reported findings and study design
Patients received ten daily intramuscular injections or were followed without Retinalamin. The team used optical coherence tomography (OCT) and pattern and full-field electroretinography (ERG) at baseline, month 1 and month 3.
Population or model 56 people with type 1 or type 2 diabetes and retinopathy without active macular edema. Retinalamin and comparison arms each included 28 people (56 eyes).
Dose, route and schedule
Ten daily intramuscular injections, with assessments at baseline and months 1 and 3. The papers leave the mass per injection unspecified. The earlier paper describes the Diopsys functional assessment in the same clinical groups.
Protocol source ↗ · Companion functional paper, confirmed cohort reuse in the later article
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Ganglion-cell complex (GCL++) | 105.45 to 109.14 µm at month 3 | 103.46 to 101.50 µm in controls · p = 0.047 for treated group versus baseline |
| Full-field ERG magnitude | 0.77 to 0.87 µV at month 3 | 0.91 to 0.88 µV in controls · p = 0.0489 for treated group versus baseline |
| Ganglion-cell and inner plexiform layers (GCL+) | 63.69 µm at baseline, 61.55 µm at month 1, 65.79 µm at month 3 | 65.04, 64.50 and 63.43 µm in controls |
Selected OCT and ERG means by visit
| Measure and group | Baseline | Month 1 | Month 3 | Month 3 vs baseline |
|---|---|---|---|---|
| GCL++ (µm), Retinalamin | 105.45 | 106.76 | 109.14 | p = 0.047 |
| GCL++ (µm), comparison | 103.46 | 102.81 | 101.50 | p unspecified |
| Nerve fiber layer (µm), Retinalamin | 41.66 | 43.10 | 43.41 | p = 0.048 |
| Nerve fiber layer (µm), comparison | 38.43 | 38.31 | 38.07 | p unspecified |
| Pattern ERG magnitude at 100% (µV), Retinalamin | 0.98 | 1.20 | 1.18 | p = 0.028 |
| Pattern ERG magnitude at 100% (µV), comparison | 1.27 | 1.26 | 1.26 | p unspecified |
| Full-field ERG magnitude (µV), Retinalamin | 0.77 | 0.85 | 0.87 | p = 0.0489 |
| Full-field ERG magnitude (µV), comparison | 0.91 | 0.92 | 0.88 | p unspecified |
The publication provides confidence intervals for arm means. The p values shown test change within the Retinalamin arm.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 56 people with type 1 or type 2 diabetes and retinopathy without active macular edema. Retinalamin and comparison arms each included 28 people (56 eyes).
- Source reviewed
- Original Russian full article, Tables 1–2 and companion functional report.
Study limitations
- The authors explicitly reuse the clinical groups from their earlier functional paper. These are two reports on one 56-person cohort.
- The groups start with different retinal electrical readings. The reported p values compare treated patients with their own baseline. The paper leaves group assignment, masking and the handling of measurements from both eyes unclear.
- These measures track retinal structure and electrical function. The data leave vision preservation and long-term disease progression unanswered.
Reviewed 2026-11-16.
Randomized study in people · 2026
Retinalamin versus placebo over two years in 21 patients with age-related macular degeneration
At 720 days, mean light sensitivity in dry AMD eyes rose by 3.27 dB with Retinalamin and fell by 4.14 dB with placebo, a reported difference in change of 7.41 dB (p < 0.001). In treated wet AMD eyes, the within-group increase was statistically inconclusive (p = 0.302).
Dry AMD mean retinal light sensitivity · +3.27 ± 1.03 dB with Retinalamin · −4.14 ± 2.11 dB with placebo · Day 720 · Between-arm difference in change +7.41 dB (p < 0.001)
Study notes and original source
Retinalamin versus placebo over two years in 21 patients with age-related macular degeneration
Repeated intramuscular Retinalamin versus placebo · Original journal report
V. V. Neroev, S. V. Milash · Russian Ophthalmological Journal. 2026;19(4 Suppl):33–40.
At 720 days, mean light sensitivity in dry AMD eyes rose by 3.27 dB with Retinalamin and fell by 4.14 dB with placebo, a reported difference in change of 7.41 dB (p < 0.001). In treated wet AMD eyes, the within-group increase was statistically inconclusive (p = 0.302).
Results and tables
Reported findings and study design
Randomized comparison with threshold microperimetry at 76 retinal locations using the Nidek MP-3. Follow-up visits ran from day 90 to day 720. Dry and wet measurements came from fellow eyes in the same participants.
Population or model 21 people, each with dry AMD in one eye and wet AMD in the other. Retinalamin: 11 people (22 eyes). Placebo: 10 people (20 eyes).
Dose, route and schedule
The companion electroretinography paper describes eight 10-day intramuscular courses at 90-day intervals. The accessible abstracts leave the mass per dose unspecified.
Protocol source ↗ · Companion paper from the same journal supplement
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Dry AMD mean retinal light sensitivity | +3.27 ± 1.03 dB with Retinalamin | −4.14 ± 2.11 dB with placebo · Day 720 · Between-arm difference in change +7.41 dB (p < 0.001) |
| Wet AMD mean retinal light sensitivity | The within-arm increase with Retinalamin was inconclusive (p = 0.302) | −3.57 ± 0.94 dB with placebo · Day 720 · Reported between-arm difference in change +5.57 dB (p < 0.001) |
| Dry AMD eyes without relative blind spots on testing | 27.3% to 100% with Retinalamin (p = 0.002) | All placebo eyes had relative blind spots by day 180 |
| Companion electroretinography report | The authors describe differences favoring Retinalamin across most electrical response measures. | Exact estimates for individual electrical endpoints require the full tables. |
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 21 people, each with dry AMD in one eye and wet AMD in the other. Retinalamin: 11 people (22 eyes). Placebo: 10 people (20 eyes).
- Source reviewed
- Original Russian abstracts for the microperimetry and companion electroretinography reports.
Study limitations
- The two supplement papers match on sample size, eye diagnoses, intervention and 720-day follow-up, and the microperimetry paper cites the electroretinography paper. They are treated as one cohort. The relationship to the larger RetinGero trial remains unconfirmed.
- The abstracts leave masking, withdrawals, other eye treatments and adverse-event counts unclear. The study results describe how the retina responded to testing. Effects on visual acuity and disease progression remain unclear.
Reviewed 2026-11-16.
Observational study · 2015
Retinalamin in retinal dystrophy: a 46-patient long-term comparison
Visual acuity improved after the first course in 18/31 Retinalamin recipients and 4/15 comparison patients. After 23–25 years, 6/9 patients with pigmentary retinal dystrophy in the longer-treatment group had residual or object vision versus 0/11 comparison patients.
Visual acuity improved after the first course · 18/31 (58.1%) with Retinalamin and 4/15 (26.7%) with conventional medications, calculated from the visual acuity categories in Table 1.
Study notes and original source
Retinalamin in retinal dystrophy: a 46-patient long-term comparison
Parabulbar Retinalamin, repeated courses · Original journal report
M. I. Razumovskiy, K. M. Pavlyuchenko, A. M. Razumovskaya · Ophthalmology in Russia. 2015;12(2):43–47. The DOI string carries a different page range.
Visual acuity improved after the first course in 18/31 Retinalamin recipients and 4/15 comparison patients. After 23–25 years, 6/9 patients with pigmentary retinal dystrophy in the longer-treatment group had residual or object vision versus 0/11 comparison patients.
Results and tables
Reported findings and study design
Retinalamin 5 mg by parabulbar injection daily for 10 days (50 mg per course), repeated one to two times per year. The paper compares 20 people with 5–7 years of courses, 11 with 23–25 years of courses and 15 given conventional medications.
Population or model 46 patients (92 eyes): 20 received Retinalamin for 5–7 years, 11 for 23–25 years, and 15 received conventional care.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Visual acuity improved after the first course | 18/31 (58.1%) with Retinalamin and 4/15 (26.7%) with conventional medications, calculated from the visual acuity categories in Table 1. | |
| Retinal pigmentary degeneration at long-term follow-up | After 23–25 years of Retinalamin, 5/9 had residual vision (0.02–0.04), 1/9 had object vision (0.1 or higher) and 3/9 had complete blindness. All 11 conventional-care patients in this diagnostic subgroup had complete blindness. | |
| Pigmentary degeneration after shorter exposure | Of 15 who received Retinalamin for the first 5–7 years, 5 retained residual vision and 10 had complete blindness at long-term assessment. |
The long-term comparison is observational. Duration groups reflect access to repeated courses, with potential differences in baseline severity and retention.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 46 patients (92 eyes): 20 received Retinalamin for 5–7 years, 11 for 23–25 years, and 15 received conventional care.
- Source reviewed
- Original bilingual full article, methods and Tables 1 and 4.
Study limitations
- Treatment groups were defined by access to repeated courses. Selection, baseline differences and retention can influence the long-term comparison.
- The paper reports patients and eyes separately. The reported outcomes do not establish a separate independent effect for each eye.
- This study examines pigmentary degeneration and retinal abiotrophy, distinct diagnoses from the early macular degeneration dissertation.
Reviewed 2026-11-16.
Comparison in people · 2021
Retinalamin with Cortexin and Ventfort Lingval in dry age-related macular degeneration
Visual acuity went from 0.71 to 0.76 with Retinalamin alone and from 0.76 to 0.88 with the combination. This comparison used electrophoresis for the two added preparations.
Study notes and original source
Retinalamin with Cortexin and Ventfort Lingval in dry age-related macular degeneration
Temporal paravascular Retinalamin injections with or without Cortexin and Ventfort Lingval by electrophoresis · Original journal report
A. V. Derkach, S. V. Trofimova · Vrach. 2021;32(5):85–87.
Visual acuity went from 0.71 to 0.76 with Retinalamin alone and from 0.76 to 0.88 with the combination. This comparison used electrophoresis for the two added preparations.
Results and tables
Reported findings and study design
Five courses, repeated one to two times per year. The methods list temporal paravascular Retinalamin 5 mg daily for 10 days in both groups. In the combination group, Cortexin and Ventfort Lingval were given by cathodal drug electrophoresis daily for five days, 20 minutes per session at up to 0.1 mA/cm². Active mass for the two electrophoresis preparations was unspecified.
Population or model 38 patients (76 eyes) with nonexudative macular degeneration: 20 Retinalamin alone, 18 the combination.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Visual acuity | Retinalamin alone 0.71 ± 0.05 to 0.76 ± 0.04. Combination 0.76 ± 0.05 to 0.88 ± 0.04. | |
| Electroretinogram a-wave amplitude | Retinalamin alone 21.2 ± 1.5 to 28.1 ± 1.7 µV. Combination 21.4 ± 1.5 to 33.9 ± 1.5 µV. | |
| Electroretinogram b-wave amplitude | Retinalamin alone 173.7 ± 8.1 to 222.7 ± 6.6 µV. Combination 172.8 ± 8.6 to 250.0 ± 7.3 µV. |
The combination adds two preparations and a different procedure. The report supplies no treatment-specific estimate for Cortexin or Ventfort Lingval and no between-group confidence intervals.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 38 patients (76 eyes) with nonexudative macular degeneration: 20 Retinalamin alone, 18 the combination.
- Source reviewed
- Original Russian article, treatment methods and Tables 1 and 2.
Study limitations
- The report gives no randomization or masking method and the groups start with different acuity values. The contribution of each added preparation and electrophoresis cannot be isolated.
- The methods name Retinalamin but also describe Retilin in the adjacent text. The authors leave the mass applied by electrophoresis unspecified.
- The narrative percentages lack clear denominators. The tables contain no between-group p values or confidence intervals. Independent overlap with other retina cohorts is unspecified.
Reviewed 2026-11-16.
Randomized study in people · 2013
Normophthal added to Retinalamin for early age-related macular degeneration
After 40 days, uncorrected visual acuity in the 45–59-year subgroup was 0.62 with adjunctive Normophthal and 0.60 with Retinalamin alone. The author reports no significant additional clinical effect in the oldest subgroup.
Study notes and original source
Normophthal added to Retinalamin for early age-related macular degeneration
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Oral Normophthal after injected Retinalamin versus injected Retinalamin alone · Dissertation author abstract
Format: Reproduction of Russian author abstract · Reviewed: See scope
A. V. Gorbunov · Candidate of Medical Sciences dissertation author abstract. St. Petersburg, 2013. Catalogue identifier 005531262.
After 40 days, uncorrected visual acuity in the 45–59-year subgroup was 0.62 with adjunctive Normophthal and 0.60 with Retinalamin alone. The author reports no significant additional clinical effect in the oldest subgroup.
Results and tables
Reported findings and study design
67 patients received combination treatment and 53 received Retinalamin only. The author describes stratified randomization. Visual testing occurred at baseline, day 40 and three months after treatment.
Population or model 120 patients with early age-related macular degeneration, 213 eyes: 67 in the combination group and 53 in the Retinalamin group.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Study regimen | Both groups received 5 mg Retinalamin by parabulbar injection each day for 10 days. The combination group then received 100 µg Normophthal orally twice daily for 30 days. | |
| Uncorrected visual acuity at day 40, ages 45–59 | 0.62 ± 0.04 with the combination and 0.60 ± 0.04 with Retinalamin alone. The reported pretreatment value was 0.47 ± 0.04. | |
| Oldest subgroup, ages 75–89 | The author reports no significant additional clinical effect with Normophthal in this subgroup. |
The author abstract identifies the Ophthalmology Laboratory of the St. Petersburg Institute of Bioregulation and Gerontology as the research institution. Both groups received Retinalamin.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 120 patients with early age-related macular degeneration, 213 eyes: 67 in the combination group and 53 in the Retinalamin group.
- Source reviewed
- Russian author abstract, methods and results on pages 10–21. The full dissertation was unavailable.
Study limitations
- The author reports stratified randomization. Details of concealment and masking are unavailable.
- The 45–59-year result is one age subgroup. The cited values alone do not establish a statistically significant difference between arms.
- The 45-patient 2013 Kazakhstan paper is a separate publication with different authors and group sizes. The available records do not establish cohort overlap.
Reviewed 2026-11-16.
Comparison in people · 2016
One versus two Retinalamin courses in dry age-related macular degeneration
In 90 patients, the authors reported improved retinal electrical responses in 80% of early or intermediate cases after treatment. More than 70% of atrophic cases improved after the repeat course.
Study notes and original source
One versus two Retinalamin courses in dry age-related macular degeneration
V. V. Neroev, O. V. Zaitseva, T. D. Okhotsimskaya, I. V. Tsapenko, E. P. Lantukh · Russian Ophthalmological Journal. 2016;(1):39–46.
In 90 patients, the authors reported improved retinal electrical responses in 80% of early or intermediate cases after treatment. More than 70% of atrophic cases improved after the repeat course.
Results and tables
Reported findings and study design
The Helmholtz institute group compared one versus two courses over six months using multifocal electroretinography and other eye assessments.
Population or model 90 adults aged 47–75 with dry AMD, contributing 180 eyes. One course: 30 people. Repeat course: 60 people.
Dose, route and schedule
Retinalamin 5 mg intramuscularly daily for 10 days. Sixty participants repeated the same course after three months. Thirty received one course.
Protocol source ↗ · Original Russian journal PDF, abstract, methods and longitudinal results.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Multifocal electroretinography in early or intermediate AMD | Favorable change reported in 80% of cases | Peak two months after the first course |
| Multifocal electroretinography in atrophic AMD | Favorable change in more than 70% of cases after the repeat course | Peak at month 5 |
Source for these results ↗ · Reviewed 2026-11-15
- Population / setting
- 90 adults aged 47–75 with dry AMD, contributing 180 eyes. One course: 30 people. Repeat course: 60 people.
- Source reviewed
- Original Russian journal PDF, abstract, methods and longitudinal results.
Study limitations
- Both groups received active drug. Percentages refer to disease-stage groups described in the paper. Eyes from the same patient are correlated. The retinal electrical response does not establish slower progression or less vision loss.
Reviewed 2026-11-15.
Trial protocol and enrollment update · 2025
RetinGero dry AMD trial: protocol and preliminary enrollment
RetinGero plans a 240-person placebo-controlled comparison. The protocol article reports 187 enrolled and baseline data for 170 as of January 3, 2025. Comparative efficacy results are pending in the checked publication.
Study notes and original source
RetinGero dry AMD trial: protocol and preliminary enrollment
· Published trial protocol and recruitment update
A. V. Kuroyedov, E. V. Balandina, O. V. Gaponko, and colleagues · Russian Journal of Clinical Ophthalmology. 2025;25(4):250–256.
RetinGero plans a 240-person placebo-controlled comparison. The protocol article reports 187 enrolled and baseline data for 170 as of January 3, 2025. Comparative efficacy results are pending in the checked publication.
Results and tables
Reported findings and study design
The patent gives no measured outcomes
Multicenter double-blind randomized comparison. The Mandryka military hospital ophthalmology center coordinates the trial with Pirogov University. Assessments include visual acuity, contrast sensitivity, OCT drusen measures and conversion to advanced AMD.
Dose, route and schedule
The protocol lists a 5 mg Retinalamin vial. It specifies one intramuscular injection per day for 10 days, repeated for eight courses spaced three months apart. The comparator is a matching schedule of placebo injections.
Protocol source ↗ · Original protocol, planned assessments and dated enrollment data.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Planned randomization | 240 participants, 120 per arm | |
| Documented enrollment and baseline data | 187 enrolled. Baseline data available for 170 (84 and 86 by masked group). | January 3, 2025 |
| Completed the full cycle | 4 participants | September 1, 2025 |
The published figures describe recruitment and data availability.
Source for these results ↗ · Reviewed 2026-11-15
- Population / setting
- Adults aged 60–80 with early or intermediate dry AMD in the study eye and a history of wet AMD in the fellow eye. 240 planned, 120 per group.
- Source reviewed
- Original protocol, planned assessments and dated enrollment data.
Study limitations
- Screening, enrollment, available baseline data and completion represent different denominators. The protocol article gives no between-group efficacy result.
Reviewed 2026-11-15.
Comparison in people · 2022
Retinalamin schedules and visual-field testing in advanced glaucoma
Retinal photosensitivity did not change significantly in this 17-patient schedule comparison. Both groups received Retinalamin.
Study notes and original source
Retinalamin schedules and visual-field testing in advanced glaucoma
D. A. Dorofeev and colleagues · Russian Open Medical Journal. 2022;11:e0109.
Retinal photosensitivity did not change significantly in this 17-patient schedule comparison. Both groups received Retinalamin.
Results and tables
Reported findings and study design
Two active schedules compared with automated visual-field testing on different devices and programs.
Population or model 17 adults with advanced primary open-angle glaucoma, 34 eyes. Nine received courses every three months and eight every six months.
Dose, route and schedule
Repeat courses every three or six months. The paper describes intramuscular delivery. The administered mass was not verified from this report.
Protocol source ↗ · Original journal full text, methods and Tables 1–3.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Retinal photosensitivity | No statistically significant change | |
| Mean deviation across testing programs | −0.36 dB | 95% CI −4.27 to 3.54 |
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 17 adults with advanced primary open-angle glaucoma, 34 eyes. Nine received courses every three months and eight every six months.
- Source reviewed
- Original journal full text, methods and Tables 1–3.
Study limitations
- No untreated arm. The 2024 OCT report has the same center, group sizes and schedules. It likely describes the same subgroup.
Reviewed 2026-11-14.
Comparison in people · 2024
Retinalamin schedules and OCT measurement agreement in advanced glaucoma
Baseline agreement between OCT devices for retinal nerve fiber layer thickness was 0.69 in manual mode and 0.73 in automatic mode. Agreement for macular volume was 0.21 in both modes.
Study notes and original source
Retinalamin schedules and OCT measurement agreement in advanced glaucoma
D. A. Dorofeev, A. A. Antonov, I. V. Kozlova, and colleagues · Russian Open Medical Journal. 2024;13:e0307.
Baseline agreement between OCT devices for retinal nerve fiber layer thickness was 0.69 in manual mode and 0.73 in automatic mode. Agreement for macular volume was 0.21 in both modes.
Results and tables
Reported findings and study design
Investigators used two OCT systems, tested manual and automated segmentation, and calculated Lin’s concordance correlation coefficients.
Population or model 17 adults, 34 eyes. Nine patients on the three-month schedule and eight on the six-month schedule.
Dose, route and schedule
Intramuscular Retinalamin courses at three- or six-month intervals. Structural OCT was performed at baseline and after three and six months. Drug mass was not verified from the report.
Protocol source ↗ · Original PDF, methods and optical coherence tomography agreement results.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Retinal nerve fiber layer thickness agreement | 0.69 manual and 0.73 automatic | 95% CI 0.51–0.81 and 0.57–0.84, respectively |
| Macular volume agreement | 0.21 in both modes |
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 17 adults, 34 eyes. Nine patients on the three-month schedule and eight on the six-month schedule.
- Source reviewed
- Original PDF, methods and optical coherence tomography agreement results.
Study limitations
- Both groups received Retinalamin. Device agreement does not establish clinical benefit. The same center and schedules appear in the 2022 visual-field report.
Reviewed 2026-11-14.
Laboratory analysis · 2017
Amino-acid analysis of Pineamin and three organ peptide preparations
This is analytical chemistry, with hydrolysis-released amino acids.
Study notes and original source
Amino-acid analysis of Pineamin and three organ peptide preparations
Free and hydrolysis-released amino acids; the measurements do not identify intact peptide sequences. · Original journal article
Format: Original publisher text and Table 2 checked; selected three-batch arithmetic audited, original PDF not recovered · Reviewed: Reported methods, results and evidence limitations
A. O. Rudenko, T. E. Eltysheva, M. M. Dyakonov · Bulletin of the Russian Military Medical Academy. 19(1):129–136
Pineamin’s reported measured amino-acid total was 731.23 µg/mg of lyophilizate. Taurine and ornithine were detected, and three reported batch averages do not match the displayed batch values.
Results and tables
Reported findings and study design
Pineamin’s reported measured amino-acid total was 731.23 µg/mg of lyophilizate. Taurine and ornithine were detected, and three reported batch averages do not match the displayed batch values.
Laboratory composition comparison of Cortexin, Cerebrolysin, Retinalamin and Pineamin; three Pineamin manufacturing batches
Population or model Laboratory composition comparison of Cortexin, Cerebrolysin, Retinalamin and Pineamin; three Pineamin manufacturing batches
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Pineamin · reported amino-acid total | 731.23 µg/mg lyophilizate | Batch totals 736.5, 713.7 and 743.5 µg/mg; Table 2. |
| Pineamin · selected amino acids | Glu 168.23; Asp 82.70; Lys 67.80; taurine 7.93; ornithine 18.47 µg/mg | Reported Table 2 averages; these do not identify intact peptides. |
| Retinalamin · measured amino-acid total | 563.74 µg/mg lyophilizate | Table 2 comparator; taurine 4.1 µg/mg, ornithine not displayed. |
| Cortexin versus Cerebrolysin · composition | Higher Cortexin amounts of several amino acids per mg of preparation | The authors report roughly 6.5–7-fold for Asp, Glu and Tyr, ninefold for serine and twelvefold for arginine. This is a chemical comparison. |
| Batch-average discrepancies | Met 8.55 reported vs 7.50 recalculated; Ile 22.35 vs 27.73; Leu 39.50 vs 33.53 µg/mg | Arithmetic means calculated from the three displayed values. The cause of the disagreement is unresolved. |
Table 2 · selected Pineamin batch values (µg/mg)
| Analyte | Batch 1 | Batch 2 | Batch 3 | Printed mean | Recalculated mean if discrepant |
|---|---|---|---|---|---|
| Asp | 86 | 78.3 | 83.8 | 82.70 | — |
| Glu | 171.1 | 161.6 | 172 | 168.23 | — |
| Lys | 67.5 | 65.8 | 70.1 | 67.80 | — |
| Taurine | 9.15 | 7.27 | 7.37 | 7.93 | — |
| Ornithine | 18.7 | 20.6 | 16.1 | 18.47 | — |
| Met | 8.29 | 8.81 | 5.41 | 8.55 | 7.50 |
| Ile | 21.9 | 38.5 | 22.8 | 22.35 | 27.73 |
| Leu | 38.6 | 21.6 | 40.4 | 39.50 | 33.53 |
| Total | 736.5 | 713.7 | 743.5 | 731.23 | — |
Selected published rows. Recalculated values identify reporting inconsistencies; the printed averages are preserved. These are amino acids measured in the preparation, not individual peptide sequences.
Chemical characterization helps distinguish the preparations. It cannot establish that amino-acid contents explain stress resistance, and it does not identify which peptides were present.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Laboratory composition comparison of Cortexin, Cerebrolysin, Retinalamin and Pineamin; three Pineamin manufacturing batches
- Source reviewed
- Original publisher text and Table 2 checked; selected three-batch arithmetic audited, original PDF not recovered
Study limitations
- Amino-acid totals are not the molecular-mass distribution or an inventory of intact peptides.
- The mass denominator and formulation excipients matter when comparing liquid and lyophilized organ preparations.
- Some values in the published table conflict.
Reviewed 2026-11-08.
Experiment described in a patent · 2009
Retinalamin plus Cortexin: optic-nerve and retinal method — RU2373904C1
Visual improvement was reported in some eyes, with a persistent non-response in a blind eye.
Study notes and original source
Retinalamin plus Cortexin: optic-nerve and retinal method — RU2373904C1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Ольга Геннадьевна Гусаревич (RU), Ольга Геннадьевна Гусаревич, Анна Аркадьевна Гусаревич (RU), Анна Аркадьевна Гусаревич, Анжелла Жановна Фурсова (RU), Анжелла Жановна Фурсова · RU2373904C1 · patent family 41476515
Visual improvement was reported in some eyes, with a persistent non-response in a blind eye.
Results and tables
Reported patent results
Reported findings
Visual improvement was reported in some eyes, with a persistent non-response in a blind eye.
Two illustrative eye-disease cases receiving Retinalamin, Cortexin and physical-treatment procedures.
Population or model Two illustrative eye-disease cases receiving Retinalamin, Cortexin and physical-treatment procedures.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Glaucoma case: right eye | Corrected visual acuity 0.3 → 0.5; total visual-field expansion reported as 40° | Combined care in one 76-year-old patient · After a 10-day course |
| Glaucoma case: left eye | Visual acuity remained 0 | The eye had longstanding blindness; no recovery was reported · After the course |
| Other case: left eye at discharge | Visual acuity reported as 0.2, without correction | An individual post-treatment value, not a group mean |
Two selected cases and multiple procedures cannot establish either peptide preparation’s independent effect, safety of the route, or a reliable comparative benefit.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Two illustrative eye-disease cases receiving Retinalamin, Cortexin and physical-treatment procedures.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- Combined treatment and patent case examples do not establish either extract's independent benefit or validate a new administration route.
- Two selected cases and multiple procedures cannot establish either peptide preparation’s independent effect, safety of the route, or a reliable comparative benefit.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Experiment described in a patent · 2002
Retinalamin / Cortexin: local ocular delivery method — RU2195297C2
The patent reports visual gains and persistence over follow-up, with two advanced-disease eyes showing no objective benefit.
Study notes and original source
Retinalamin / Cortexin: local ocular delivery method — RU2195297C2
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
И.Б. Максимов, В.Х. Хавинсон, Л.К. Мошетова, Г.В. Анисимова · RU2195297C2 · patent family 20229433
The patent reports visual gains and persistence over follow-up, with two advanced-disease eyes showing no objective benefit.
Results and tables
Reported patent results
Reported findings
The patent reports visual gains and persistence over follow-up, with two advanced-disease eyes showing no objective benefit.
Uncontrolled patent report of 65 patients (80 eyes), aged 18–80, receiving local delivery of retina- or cortex-derived preparations.
Population or model Uncontrolled patent report of 65 patients (80 eyes), aged 18–80, receiving local delivery of retina- or cortex-derived preparations.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Visual acuity and fields | Acuity increases of 0.01–0.4 and field expansion averaging 10–15° reported | Before/after; not an untreated comparison · 1 week |
| Additional acuity and field changes | Acuity increased a further 0.05–0.2; fields expanded a further 5–10° | Relative to the preceding examination, as described · 1 month |
| Persistence and non-response | Results described as stable at 3 and 6 months; no objective positive effect in two advanced-disease eyes | Follow-up duration varied from 1 to 6 months |
| Reported tolerability | No allergic or adverse effects reported | Uncontrolled reporting does not establish safety of invasive delivery |
Heterogeneous diagnoses, non-independent eyes and absence of a concurrent control prevent causal inference. Results cannot be assigned to both extracts as if each had been independently tested.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Uncontrolled patent report of 65 patients (80 eyes), aged 18–80, receiving local delivery of retina- or cortex-derived preparations.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- This is a delivery-method disclosure, not proof of safety or superiority of an invasive route. It must not be counted as independent clinical replication without checking related reports.
- Heterogeneous diagnoses, non-independent eyes and absence of a concurrent control prevent causal inference. Results cannot be assigned to both extracts as if each had been independently tested.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Randomized study in people · 2020
The influence of long-term retinal protective therapy on glaucoma progression according to structural and functional tests
Retinal nerve-fiber thickness remained stable within the treated group and declined within controls, but endpoint differences between groups were not significant. Visual acuity and mean deviation did not significantly change; pattern standard deviation worsened in both groups.
Study notes and original source
The influence of long-term retinal protective therapy on glaucoma progression according to structural and functional tests
Retinalamin tissue-derived preparation
Strakhov VV, Egorov EA, Erichev VP, Yartsev AV, Petrov SY, Dorofeev DA · Vestnik oftalmologii. 2020;136:58-66.
Retinal nerve-fiber thickness remained stable within the treated group and declined within controls, but endpoint differences between groups were not significant. Visual acuity and mean deviation did not significantly change; pattern standard deviation worsened in both groups.
Results and tables
Reported findings and study design
147 glaucoma patients, 249 eyes: Retinalamin 69 patients/119 eyes versus control 78/130. Repeat courses every six months; assessments every three months for 24 months.
Population or model 147 patients (249 eyes), randomized; 24 months
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Visual acuity/refraction | No change in either group | p>0.05 |
| IOP | Increased in controls (p=0.033); end-of-study groups not different | between-group p=0.87 |
| Mean deviation change | Not significant in either group | p=0.45 treated; p=0.27 control |
| PSD, treated | 4.84 ± 3.21 → 6.01 ± 2.584 dB | p=0.0004 |
| PSD, control | 3.46 ± 2.23 → 5.86 ± 2.26 dB | p<0.0001 |
| PSD between groups | Baseline p=0.02; end p=0.53 | |
| MD between groups | Baseline p=0.15; end p=0.59 | |
| RNFL | Treated change p=0.078; control 83.5 ± 22.47 → 76.7 ± 20.7 μm (p=0.001) | Between groups: baseline p=0.276; end p=0.524 |
| Neuroretinal rim | Treated 222 ± 88.94 → 231 ± 99.3 (p=0.012); control 248 ± 87.09 → 234 ± 96.2 (p=0.0006) | Between groups p=0.109 baseline; p=0.909 end; units not given |
| Ganglion-cell-layer thickness | No significant changes | Within groups p=0.211/0.16; between groups p=0.44/0.51 |
Within-group significance is not evidence of a significant treatment-versus-control difference. Patient and eye counts are kept distinct.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 147 patients (249 eyes), randomized; 24 months
- Source reviewed
- PubMed-indexed abstract and bibliographic metadata checked via Europe PMC; full methods not appraised.
Study limitations
- Within-group significance is not evidence of a between-group treatment effect.
- Blinding and adjustment for two eyes per participant require full-methods review.
Reviewed 2026-10-07.
Animal research · 2021
Retinoprotective effects of Retinalamin studied in an experimental model of photochemical damage to rabbit retinas
Retinalamin did not significantly improve electroretinography, retinal morphology or apoptosis measures versus saline in this photochemical retinal-injury model.
Retinal functional changes after injury · Declines on days 10/20 · p<0.001 versus baseline
Study notes and original source
Retinoprotective effects of Retinalamin studied in an experimental model of photochemical damage to rabbit retinas
Retinalamin tissue-derived preparation
Suetov AA, Alekperov SI, Odinokaya MA, Kostina AA · Vestnik oftalmologii. 2021;137:57-67.
Retinalamin did not significantly improve electroretinography, retinal morphology or apoptosis measures versus saline in this photochemical retinal-injury model.
Results and tables
Reported findings and study design
36 rabbits, 72 eyes, randomized into four equal groups. Retinalamin 0.25 mg/kg parabulbar for ten days, starting day 1 or 10; matching saline groups. Injury: 405 nm light, 5 mW/cm², four hours/day for 20 days.
Population or model 36 rabbits (72 eyes), four randomized groups
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Retinal functional changes after injury | Declines on days 10/20 | p<0.001 versus baseline |
| Retinalamin versus saline | No significant difference on any measured endpoint | p>0.05 |
| Assessment times | Baseline and days 10, 20 and 30 |
Rabbit photochemical-injury model; the negative drug comparison is preserved.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 36 rabbits (72 eyes), four randomized groups
- Source reviewed
- PubMed-indexed abstract and bibliographic metadata checked via Europe PMC; full methods not appraised.
Study limitations
- A negative result in one injury model does not settle other indications, but should accompany positive preclinical reports.
- Animal outcomes do not establish human effectiveness or safety.
Reviewed 2026-10-07.
Observational study · 2025
Neuroprotective therapy in advanced primary open-angle glaucoma
The treated cohort had smaller annual declines in visual-field mean deviation and retinal nerve-fiber thickness than untreated controls. Intraocular pressure was controlled in both groups.
MD decline per year · 0.98 (0.78;1.76) versus 1.65 (0.59;1.79) dB/year
Study notes and original source
Neuroprotective therapy in advanced primary open-angle glaucoma
Retinalamin tissue-derived preparation
Dorofeev DA, Kozlova IV, Vereshchagina AI · Vestnik oftalmologii. 2025;141:75-80.
The treated cohort had smaller annual declines in visual-field mean deviation and retinal nerve-fiber thickness than untreated controls. Intraocular pressure was controlled in both groups.
Results and tables
Reported findings and study design
56 advanced-glaucoma patients, 98 eyes; prospective two-center observation, 2022–2024. Treated patients received ten IM injections of Retinalamin 5 mg every three months for two years.
Population or model 56 patients (98 eyes), advanced glaucoma; prospective two-center cohort, 2022–2024
Dose, route and schedule
Retinalamin: a course of ten intramuscular injections, 5 mg per injection, repeated every three months over two years. The abstract does not specify the interval between injections within each course.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| MD decline per year | 0.98 (0.78;1.76) versus 1.65 (0.59;1.79) dB/year | |
| PSD increase per year | 0.02 (−0.3;1.2) versus 0.3 (0.7;1.3) dB/year | |
| RNFL loss per year | 1.5 (−0.25;5.0) versus 3.0 (0.75;10.2) μm/year |
Parentheses reproduce the reported intervals without assuming their type. The control PSD interval does not contain its central value as printed; this inconsistency is retained.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 56 patients (98 eyes), advanced glaucoma; prospective two-center cohort, 2022–2024
- Source reviewed
- PubMed-indexed abstract and bibliographic metadata checked via Europe PMC; full methods not appraised.
Study limitations
- Nonrandomized cohort; treatment selection and other confounding may explain part of the difference.
- The abstract does not establish a blinded comparison or a causal reduction in vision loss.
Reviewed 2026-10-07.
Randomized study in people · 2019
Structural and functional changes in the retina of patients with primary open-angle glaucoma and compensated intraocular pressure while undergoing retinoprotective therapy
Visual-field indices improved within the treated group while declining in controls. Visual acuity did not change; retinal nerve-fiber thickness and neuroretinal-rim volume remained stable in both groups. Electrophysiological results varied by measure.
Study notes and original source
Structural and functional changes in the retina of patients with primary open-angle glaucoma and compensated intraocular pressure while undergoing retinoprotective therapy
Retinalamin tissue-derived preparation
Egorov EA, Erichev VP, Strakhov VV, Petrov SY, Romanova TB, Vasina MV, Zinina VS, Makarova AS, Kazanova SY, Yartsev AV · Vestnik Oftalmologii. 2019;135(3):20–30.
Visual-field indices improved within the treated group while declining in controls. Visual acuity did not change; retinal nerve-fiber thickness and neuroretinal-rim volume remained stable in both groups. Electrophysiological results varied by measure.
Results and tables
Reported findings and study design
180 glaucoma patients, 355 eyes, randomized 90/90. IM Retinalamin course repeated at month 6; assessments at months 1, 3, 6, 7, 9 and 12.
Population or model 180 glaucoma patients (355 eyes), randomized equally; 12 months
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Visual-acuity change | No change reported | Treated p=0.3732/0.6862; control p=0.7751 |
| IOP change | No significant change | Treated p=0.7632; control p=0.3921 |
| MD, treated | −5.52 ± 2.76 → −4.82 ± 2.73 dB | Six visit p-values: 0.0391, 0.0201, 0.0302, 0.3708, 0.0151, 0.0353 |
| MD, control | −3.51 ± 1.84 → −4.60 ± 2.61 dB | p=0.0012 |
| PSD, treated | 4.63 ± 1.60 → 4.05 ± 1.43 dB | p=0.0081 |
| PSD, control | 3.73 ± 1.19 → 4.29 ± 1.53 dB | p=0.0027 |
| RNFL/neuroretinal rim | Described as stable | Treated p=0.8039/0.9005; control p=0.7448/0.9620 |
| GCC thickness | Treated p=0.0377; control p=0.0250 | Source calls treated thickness stable despite p<0.05 |
| Treated P50 amplitude | 6.54 ± 2.61 → 6.53 ± 2.64 μV | p=0.0479 |
| Treated P50 latency | 48.39 ± 3.69 → 50.86 ± 4.09 ms | p=0.0271 |
| Control P50 amplitude/latency | Amplitude declined; latency increased | p=0.0031/0.0194 |
| N95 amplitude/latency | Treated p=0.0141/0.0492; control p=0.0195/0.3401 |
Several “stable” descriptors conflict with printed p-values. Baseline group differences and multiple testing prevent treating each within-group p-value as a treatment effect.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 180 glaucoma patients (355 eyes), randomized equally; 12 months
- Source reviewed
- PubMed-indexed abstract and bibliographic metadata checked via Europe PMC; full methods not appraised.
Study limitations
- Baseline visual-field values differed. Within-group trends alone do not quantify a between-group treatment effect.
- The analysis leaves blinding, adjustment for multiple comparisons and the handling of two eyes from the same patient unclear.
Reviewed 2026-10-07.
Review of earlier studies · 2013
Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results
Summarizes clinical work on seven named peptide preparations. Useful for tracing original Russian reports and distinguishing tissue extracts from short peptides.
Study notes and original source
Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results
Khavinson VKh, Kuznik BI, Ryzhak GA · Adv Gerontol 26(1):20-37. PMID 24003726
Summarizes clinical work on seven named peptide preparations. Useful for tracing original Russian reports and distinguishing tissue extracts from short peptides.
- Population / setting
- Originating group’s clinical and gerontology literature
- Source reviewed
- Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
- Review by investigators in the originating program; not independent replication.
- Clinical findings must be traced to the exact preparation and original study.
Reviewed 2026-09-29.
Comparison in people · 2020
Peptide bioregulators: delivery and efficacy
Compares administration routes of Retinalamin. Visual acuity did not change significantly; retinal-sensitivity results varied by disease stage and follow-up.
Group I total retinal-sensitivity change, initial/moderate/advanced disease · +122 / +166 / +124 dB · Month 3
Study notes and original source
Peptide bioregulators: delivery and efficacy
Erichev VP, Lovpache DN, Yaremenko TV · Vestn Oftalmol 136(2):56-62. PMID 32366071
Compares administration routes of Retinalamin. Visual acuity did not change significantly; retinal-sensitivity results varied by disease stage and follow-up.
Results and tables
Reported findings and study design
498 glaucoma patients/eyes as printed; group I combined IM/retrobulbar 110, group II retrobulbar 171, group III IM (count not explicitly printed). Retinalamin 5 mg per stated route; total course 50 mg. Assessments months 3 and 6.
Population or model Open-angle glaucoma; 498 patients (eyes), as worded in the abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Group I total retinal-sensitivity change, initial/moderate/advanced disease | +122 / +166 / +124 dB | Month 3 |
| Group II, initial/moderate disease | +123 / +110 dB | Advanced disease: no significant change |
| Group III, initial/moderate/advanced disease | +142 / +274 / +148 dB | |
| Durability | Regression described from month 6 in group III | |
| Visual acuity | No significant change |
These large dB totals sum threshold values across visual-field locations; they are not a single-point sensitivity increase. Patient/eye terminology is ambiguous in the abstract.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Open-angle glaucoma; 498 patients (eyes), as worded in the abstract
- Source reviewed
- Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
- All compared groups received active preparation; this does not isolate benefit versus no Retinalamin.
- Patient/eye unit wording should be checked in full text. Findings do not establish benefit for Normophthal.
Reviewed 2026-09-29.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗